Adimab Expands Collaborations with Merck and Lilly
LEBANON, N.H. -- January 8, 2013
Adimab, LLC, a technology leader in the discovery of fully human antibodies,
today announced the expansion of its existing research collaborations with
Merck and Lilly.
The latest agreement provides Merck expanded access to Adimab’s technology to
discover and optimize fully human antibody candidates, including potentially
bispecific antibody candidates, across all disease areas. Adimab scientists
will discover therapeutic antibody candidates to multiple targets nominated by
Merck over a three-year period.
“At Merck, we look at a lot of technologies and have been impressed with
Adimab’s output in our previous collaboration,” said Deborah A. Law, vice
president, Biologics Discovery, Merck Research Laboratories. “From a strategic
perspective we wanted to maintain access to their technology.”
Adimab also announced the expansion of its existing research agreement with
Lilly to include the discovery and optimization of multiple bispecific
antibodies targeting molecular targets identified by Lilly.
Pursuant to these agreements with Merck, acting through a subsidiary, and
Lilly, Adimab will receive upfront payments and is eligible to receive
preclinical and clinical development milestone payments as well as royalties
on product sales.
“We are always pleased when our existing partners choose to expand their
relationship with us,” said Tillman Gerngross, Adimab’s CEO and co-founder.
“The antibody discovery arena has become very competitive and nothing is more
validating than existing partners coming back for broader access to our
“In addition to conventional discovery and optimization programs, we are
seeing a lot of interest in our bispecific platform,” says Guy Van Meter, Vice
President of Business Development at Adimab. “We continue to build on our
leadership position in the antibody space, and I am pleased with the
validation that these transactions provide for our bispecific antibody
discovery and optimization capabilities.”
Over the past three years, Adimab has established collaborations with multiple
leading pharmaceutical companies, including Merck, Roche, Novartis, Pfizer,
Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead and Kyowa Hakko Kirin.
Adimab’s integrated antibody discovery and optimization platform provides
unprecedented speed from antigen to purified, full-length human IgGs. Adimab
offers fundamental advantages by delivering diverse panels of therapeutically
relevant antibodies that meet the most aggressive standards for affinity,
epitope coverage, species cross-reactivity and developability. Adimab enables
its partners to rapidly expand their biologics pipelines through a broad
spectrum of technology access arrangements. For more information, visit
Guy Van Meter, 603-653-5775
VP of Business Development
Press spacebar to pause and continue. Press esc to stop.